缓解与未缓解髓系白血病干细胞表面抗原CD34^+CD123^+表达差异研究

Expression Differences of Surface Markers CD34^+CD123^+ on Leukemia Stem Cells between Released and Relapsed Acute Myeloid Leukemia

目的:探索缓解与未缓解急性髓系白血病干细胞表面抗原表达差异,为判定化疗疗效及其预后提供依据。方法:按照急性白血病诊断标准,根据患者入院时骨髓白血病细胞数量多少分成临床缓解与未缓解两组,以流式细胞仪分别检测骨髓中白血病干细胞表面相关抗原表达情况,比较二者之间差异。其中经标准化疗方案治疗结束后,通过复查骨髓象判定疗效并比较化疗前后白血病干细胞表面相关抗原表达变化。结果:与缓解的急性髓系白血病患者骨髓白血病干细胞相关抗原表达值相比,未缓解的患者骨髓白血病干细胞表面相关抗原表达明显升高,差异具有统计学意义(P<0.05,0.001);未缓解的患者经标准方案化疗后骨髓虽然已经获得完全缓解,但依然具有白血病干细胞表面抗原高表达,提示这部分患者依然有复发的可能性。结论:急性髓系白血病患者的白血病干细胞相关抗原表达值升高是急性白血病复发难治的根源之一。

Objective： To investigate the differentiations of surface markers on leukemia stem cells between released and relapsed acute myeloid leukemia, and to lay the foundations for investigating the chemotherapeutic effect and prognosis. Methods： According to the standard of diagnosis of acute leukemia diseases, the hospitalized patients were divided into two groups of released and relapsed terms with their leukemia cells in the bone marrow, then the affiliated surface markers of leukemia stem cells and the expression differences between them were detected. After the standard chemotherapy, the therapeutic effect was evaluated through reviewing the myelogram. Results： Compared with surface markers on leukemia stem cells in released acute myeloid leukemia patients, surface markers in relapsed terms had been increased with statistical significance （P〈0.05, 0.001）. Although the relapsed patients got complete remission through standard chemotherapy, they still had large amounts of leukemia stem cells＇ surface markers, indicating these patients would possibly relapse. Conclusion： The rising of leukemia stem cells in acute myeloid leukemia patients is one of the foundations that induces refractory or relapsed acute leukemia.